DEF 14A: Integer Holdings Corporation Announces Proxy Statement for 2024 Annual Meeting

Integer Holdings Corporation has released its proxy statement for the 2024 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, and executive compensation.

Summary

• Integer Holdings Corporation has released its proxy statement for the 2024 Annual Meeting of Stockholders to be held on May 22, 2024.
• The proxy statement includes information on proposals to elect 11 directors, ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2024, and approve, on an advisory basis, the compensation of the company's named executive officers.
• The company's 2023 performance highlights include a 16% increase in sales to $1.597 billion, driven by medical product lines, and operating income increased $46 million or 38% to $167 million.
• Adjusted operating income increased $50 million or 26% to $241 million, and diluted earnings per share from continuing operations increased $0.73 per share or 37% to $2.69 per share.
• Adjusted earnings per share increased $0.79 per share or 20% to $4.67 per share.
• The company's executive compensation program is designed to attract, retain, and motivate executives, linking compensation to company performance and stockholder interests.
• The compensation program includes base salary, annual performance-based incentives, and long-term equity incentives.
• Last year's say-on-pay vote received the support of approximately 95% of votes cast by stockholders.
• The Board recommends voting FOR each director nominee, FOR ratification of Deloitte & Touche LLP, and FOR approval of the compensation of the named executive officers.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and strategic initiatives. The high approval rate for executive compensation also indicates confidence in management.

Positives

• The company experienced significant sales growth, with a 16% increase to $1.597 billion.
• Operating income and adjusted operating income both saw substantial increases.
• Diluted and adjusted earnings per share also increased significantly.
• Stockholders overwhelmingly supported the executive compensation program in the previous year's vote.
• The company is focused on aligning executive compensation with performance and stockholder value.

Future Outlook

The company believes it is positioned to sustainably grow sales high single digit to low double digits for years to come.

Management Comments

• The Oscor and Aran Biomedical acquisitions are performing better than expected and were strong contributors to our 2023 sales and profit growth.
• Later this year, we will open a new, state-of-the-art development and manufacturing center in Galway, Ireland, to better serve structural heart and neurovascular customers in this important medical device hub.
• Significant expansion projects are also underway in New Ross, Ireland, as well as in the Dominican Republic, Malaysia and New York to meet customer demand.

Industry Context

Integer is one of the largest medical device outsource manufacturers in the world, serving the cardiac rhythm management, neuromodulation, vascular, portable medical and orthopedics markets.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards beyond stating that the company's compensation programs are monitored against companies of similar size and complexity.
• The peer group used for executive compensation benchmarking includes companies like Avanos Medical, ICU Medical, NuVasive, Benchmark Electronics, Integra LifeSciences Holdings Corporation, Orthofix Medical Inc., Bruker Corporation, Masimo Corporation, OSI Systems, Inc., Plexus Corp., Teleflex Incorporated, Varex Imaging Corporation, and Haemonetics Corporation.

Stakeholder Impact

• The company's strong performance and strategic initiatives are expected to benefit stockholders through increased value.
• Employees may benefit from the company's growth and commitment to diversity and inclusion.
• Customers may benefit from the company's investments in capabilities and capacity to address unmet patient needs.
• The company's commitment to social and environmental responsibility may benefit the communities in which it operates.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Stockholders on May 22, 2024.

Key Dates

Keywords

proxy statement, annual meeting, executive compensation, board of directors, financial performance, Integer Holdings Corporation, Deloitte & Touche, stockholders, directors, governance